title: [New tobacco dependence drug: Varenicline, partial agonist of alpha4beta2 acetylcholine-nicotine receptors].
abstract: Most of adult smokers, up to 80 % in the Czech Republic, would prefer to stop smoking and about 40 % of them try to stop each year. Most often they stop just cold turkey and this means 98 % of them relapsing until one year. Maximum efficacy of intensive currently available treatment is about 20-25 %, so also 75-80 % intensive treated smokers relaps within one year. Available and effective treatment of tobacco dependence would influence significantly morbidity and mortality. Although we cannot expect miracle, new medication varenicline, parcial agonist of alpha4beta2 acetylcholin-nicotine receptors, seems to contribute to both to a bit higher efficacy, as well as to "medicalization" of tobacco dependence and increased availability of specialized treatment services.
authors.affiliation: Ustav hygieny a epidemiologie a Centrum lécby závislosti na tabáku III. interní kliniky 1. LF UK a VFN, Praha. eva.kralikova@lf1.cuni.cz
authors.forename: E
authors.initials: E
authors.lastname: Králíková
mesh_terms: D000818:Animals; D001552:Benzazepines / Q000627:therapeutic use*; D006801:Humans; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use*; D011978:Receptors, Nicotinic / Q000187:drug effects*; D016540:Smoking Cessation; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D011978:Receptors, Nicotinic; C403531:nicotinic receptor alpha4beta2; D000068580:Varenicline